ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO730

Bisphosphonate Utilization Across the eGFR Spectrum

Session Information

Category: Women’s Health and Kidney Diseases

  • 2000 Women’s Health and Kidney Diseases


  • Titan, Silvia M., Sao Paulo University Medical School, Sao Paulo, Brazil
  • Laureati, Paola, Karolinska Institutet, Stockholm, Sweden
  • Sang, Yingying, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
  • Levey, Andrew S., Tufts Medical Center, Boston, Massachusetts, United States
  • Chang, Alex R., Geisinger Medical Center, Danville, Pennsylvania, United States
  • Grams, Morgan, Johns Hopkins University, Baltimore, Maryland, United States
  • Inker, Lesley, Tufts Medical Center, Boston, Massachusetts, United States
  • Carrero, Juan Jesus, Karolinska Institutet, Stockholm, Sweden

KDIGO currently recommends bisphosphonate (BSP) use for osteoporosis patients with CKD G3a-G3b who have normal PTH and high risk of fractures. This study evaluated the frequency and factors associated with BSP use among osteoporosis patients from two healthcare organizations: Geisinger (2006-2017), Pennsylvania, United States; and Stockholm region (2006-2012), Sweden.


Incident osteoporosis was defined as the first ICD code for osteoporosis, and BSP use was defined as the prescription (Geisinger) or dispensation (Stockholm) of any BSP 6 months prior or up to 3 years following the diagnosis of osteoporosis. BSP use was compared across eGFR categories, accounting for the competing risk of death using multinomial logistic regression.


There were 15887 women and 3200 men in Stockholm and 23645 women and 7026 men in Geisinger with incident osteoporosis. Overall, BSP use was 55% in Stockholm and 36% in Geisinger, with lower rates in the groups with eGFR <45 ml/min/1.73m2. After adjustment for age and identified confounders, the odds of BSP prescription dropped progressively with lower eGFR, particularly in those with eGFR<60ml/min/1.73m2 (Figure 1). In Geisinger, BSP use declined significantly over time.


Our results suggest that BSP use is not high in incident osteoporosis, with infrequent use in lower eGFR. Although we lacked data on PTH and fracture risk score, this study raises concern about osteoporosis under-treatment in patients with eGFR 30-60ml/min/1.73m2.

Figure 1.


  • Other NIH Support